HealthTree Logo
search more_vert
close
person Sign In / Create Account
ASH 2022: CLL Patients' Treatment Options if Non-Covalent BTK Inhibitors Aren't Working
Posted: Feb 08, 2023
ASH 2022: CLL Patients' Treatment Options if Non-Covalent BTK Inhibitors Aren't Working image

At the ASH 2022 annual meeting, Dr. Meghan Thompson, a CLL expert from Memorial Sloan Kettering Cancer Center in New York, expressed there is an unmet need for high-risk CLL patients that have tried covalent BTK inhibitors followed by any non-covalent BTK inhibitors and have become resistant to treatment. Data gathered from treated patients in her clinic and data from clinical trials suggests a venetoclax regimen (if the patient has not yet been treated with venetoclax) or cellular-based therapies like CAR T-cell or allogeneic stem cell transplants have a high overall response rate (ORR) meaning the % of patients in which the cancer was significantly reduced. 

Watch the Full Video with Meghan Thompson, MD Here:

Non-Covalent BTK Inhibitors May Increase BTK Mutations and Treatment Resistance for CLL Patients 

The data also showed that prior to non-covalent BTK inhibitor treatment, 38.5% of the CLL patients started with the BTKC481 mutation and 33% had the PLCG2 mutation. After non-covalent BTK inhibitor treatment, 73% of the patients developed a new BTK mutation (BTKL528W, BTKV416L, and/or BTKT474I), and the PLCG2 mutation persisted leading to increased treatment resistance.

Treatment Type and ORR for CLL Patients Resistant to Non-Covalent BTK Inhibitors

Higher ORR (more favorable outcomes) 

Lower ORR (not recommended) 

  • Alternative covalent BTK inhibitor: 66.7% 
  • Chemo or chemoimmunotherapy: 18.8% 
  • Anti-CD20 antibody monotherapy (used by itself and not in a combination treatment): 0% 
  • Alternative non-covalent BTK inhibitor: 0% 
  • PI3 kinase inhibitor: 0% 

CLL patients with resistance to non-covalent BTK inhibitors are encouraged to enroll in clinical trials such as CAR T-cell therapy to help advance treatment options. 

For more information about CAR T-cell therapy and joining CAR T-cell clinical trials, see here: What is CAR T-cell Therapy?

The author Megan Heaps

about the author
Megan Heaps

Megan joined HealthTree in 2022. As a writer and the daughter of a blood cancer patient, she is dedicated to helping patients and their caregivers understand the various aspects of their disease. This understanding enables them to better advocate for themselves and improve their treatment outcomes. In her spare time, she enjoys spending time with her family. 

Thanks to our HealthTree Community for Chronic Lymphocytic Leukemia Sponsors:

Abbvie
Genentech

Follow Us

facebook instagram youtube